| Name | Title | Contact Details |
|---|
Garco Inc is a Asheboro, NC-based company in the Business Services sector.
Enviro Clean Services L L C is a Oklahoma City, OK-based company in the Business Services sector.
For more than 125 years, National Jewish Health has been at the forefront of research and medicine. We integrate the latest scientific discoveries with coordinated care for pulmonary, cardiac, immune and related conditions. National Jewish Health physicians and researchers are at the forefront of a new era in health care that embraces a personalized, preventive approach to medicine. We understand that each person is unique, and their variations in diet, environment, personal habits and DNA all influence their individual health. That is why two different people are exposed to certain conditions and only one gets sick and why certain treatments may work for one person and not for another. With a focus on personalized medicine, our researchers are looking at environment-gene interaction and making strides in predicting, preventing, treating and tracking many diseases. This proactive approach to medicine means that if you have a disease, or the probability of getting a disease, it may be detected sooner so that you may live longer, healthier and with a better quality of life. Our research is truly transforming the lives of millions. By using an individuals DNA to predict and prevent disease, to guide the right choice of therapy to limit side effects and bring higher success rates for treatments and to be able to track the effects of these therapies, National Jewish Health is working to improve health care for the future.
Cellerant Therapeutics is a clinical stage biotechnology company focused on developing human stem cell and antibody therapies for oncology applications and blood-related disorders. Cellerant`s programs include: CLT-008, an off-the-shelf cellular immunotherapy, under evaluation in a multicenter, open-label, randomized, controlled Phase 2 clinical trial in patients with de novo AML; CSC030-ADC, a preclinical monoclonal antibody drug conjugate that selectively targets and kills leukemic stem and blast cells responsible for initiating and maintaining disease; and CSC012, a preclinical monoclonal antibody targeting leukemic and pre-leukemic stem cells for acute leukemias and myelodysplastic syndromes. The Company is also developing next generation CAR product candidates leveraging its proprietary immunocellular therapy and antibody discovery and development platform.
Florida Silica Sand Co Inc is a Fort Lauderdale, FL-based company in the Business Services sector.